Evolving neurobiology of tuberous sclerosis complex

Acta Neuropathologica

Volumn 125, Issue 3, 2013, Pages 317-332

  Crino, Peter B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autism; Epilepsy; mTOR; SEGA; Tuber; Tuberous sclerosis

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1BETA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MONOCYTE CHEMOTACTIC PROTEIN 1; TUBERIN;

BRAIN DAMAGE; CLINICAL FEATURE; CORTICAL TUBER; DISEASE ACTIVITY; EPILEPTOGENESIS; GENE; GENE IDENTIFICATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; GIANT CELL TUMOR; HUMAN; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NERVE EXCITABILITY; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SUBEPENDYMAL GIANT CELL TUMOR; SUBEPENDYMAL NODULE; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS;

ANIMALS; BRAIN; CYTOKINES; DISEASE MODELS, ANIMAL; EPILEPSY; HUMANS; MICE; NEUROBIOLOGY; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84878867454     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1085-x     Document Type: Review

References (107)

1. Anderl S, Freeland M, Kwiatkowski DJ, Goto J (2011) Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Hum Mol Genet 20:4597-4604
2. Au KS, Williams AT, Roach ES, et al. (2007) Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 9:88-100
3. Baybis M, Yu J, Lee A, Golden JA, Weiner H, McKhann G II, Aronica E, Crino PB (2004) Activation of the mTOR cascade distinguishes cortical tubers from focal cortical dysplasia. Ann Neurol 56:478-487
4. Bissler JJ, McCormack FX, Young LR, et al. (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140-151
5. Boer K, Troost D, Timmermans W, Gorter JA, Spliet WG, Nellist M, Jansen F, Aronica E (2008) Cellular localization of metabotropic glutamate receptors in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Neuroscience 156:203-215
6. Boer K, Crino PB, Gorter JA, Nellist M, Jansen FE, Spliet WG, van Rijen PC, Wittink FR, Breit TM, Troost D, Wadman WJ, Aronica E (2010) Gene expression analysis of tuberous sclerosis complex cortical tubers reveals increased expression of adhesion and inflammatory factors. Brain Pathol 20:704-719
7. Boer K, Troost D, Jansen F, Nellist M, van den Ouweland AM, Geurts JJ, Spliet WG, Crino P, Aronica E (2008) Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex. Neuropathology 28:577-590
8. Carson RP, Van Nielen DL, Winzenburger PA, Ess KC (2012) Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin. Neurobiol Dis 45:369-380
9. Cepeda C, André VM, Yamazaki I, Hauptman JS, Chen JY, Vinters HV, et al. (2010) Comparative study of cellular and synaptic abnormalities in brain tissue samples from pediatric tuberous sclerosis complex and cortical dysplasia type II. Epilepsia 51(Suppl 3):160-165
10. Chan JA, Zhang H, Roberts PS, et al. (2004) Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 63:1236-1242
11. Choi YJ, Di Nardo A, Kramvis I, et al. (2008) Tuberous sclerosis complex proteins control axon formation. Genes Dev 22:2485-2495
12. Crino PB, Trojanowski JQ, Dichter MA, Eberwine J (1996) Embryonic neuronal markers in tuberous sclerosis: single-cell molecular pathology. Proc Natl Acad Sci USA. 93(24):14152-14157
13. Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355:1345-1356
14. Crino PB, Aronica E, Baltuch G, Nathanson KL (2010) Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology 74:1716-1723
15. Dabora SL, Jozwiak S, Franz DN, et al. (2001) Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 68:64-80
16. Dabora SL, Franz DN, Ashwal S, et al. (2011) Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS ONE 6:e23379
17. Davies DM, Johnson SR, Tattersfield AE, et al. (2008) Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 358:200-203
18. Davies DM, de Vries PJ, Johnson SR, et al. (2011) Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 17:4071-4081
19. Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, Finan PM, Kwiatkowski DJ, Murphy LO, Manning BD (2012) TBC1D7 Is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell 47:535-546
20. Ehninger D, Han S, Shilyansky C, et al. (2008) Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 14:843-848
21. Ehninger D, Silva AJ (2010) Rapamycin for treating tuberous sclerosis and autism spectrum disorders. Trends Mol Med. 17:78-87
22. Ellisen LW (2005) Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle 4:1500-1502
23. European Tuberous Sclerosis Consortium (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305-1315
24. Feliciano DM, Su T, Lopez J, Platel JC, Bordey A (2011) Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. J Clin Invest 121:1596-1607
25. Fukutani Y, Yasuda M, Saitoh C, Kyoya S, Kobayashi K, Miyazu K, Nakamura I (1992) An autopsy case of tuberous sclerosis. Histological and immunohistochemical study. Histol Histopathol 7:709-714
26. Gallagher A, Grant EP, Madan N, et al. (2010) MRI findings reveal three different types of tubers in patients with tuberous sclerosis complex. J Neurol 257:1373-1381
27. Gao X, Pan D (2001) TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 15:1383-1392
28. Goorden SM, van Woerden GM, van der Weerd L, Cheadle JP, Elgersma Y (2007) Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures. Ann Neurol 62:648-655
29. Goto J, Talos DM, Klein P, et al. (2011) Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci USA. 108(45):E1070-E1079
30. Grajkowska W, Kotulska K, Jurkiewicz E, Roszkowski M, Daszkiewicz P, JóÅwiak S, Matyja E (2011) Subependymal giant cell astrocytomas with atypical histological features mimicking malignant gliomas. Folia Neuropathol 49:39-46
31. Green AJ, Smith M, Yates JR (1994) Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 6:193-196
32. Henske EP, Scheithauer BW, Short MP, et al. (1996) Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 59:400-406
33. Henske EP, Wessner LL, Golden J, et al. (1997) Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 151:1639-1647
34. Hirose T, Scheithauer BW, Lopes MB, Gerber HA, Altermatt HJ, Hukee MJ, VandenBerg SR, Charlesworth JC (1995) Tuber and subependymal giant cell astrocytoma associated with tuberous sclerosis: an immunohistochemical, ultrastructural, and immunoelectron and microscopic study. Acta Neuropath 90:387-399
35. Hsu PP, Kang SA, Rameseder J, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332:1317-1322
36. Huang J, Manning BD (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412:179-190
37. Huang J, Wu S, Wu CL, Manning BD (2009) Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res 69:6107-6114
38. Jacinto E, Loewith R, Schmidt A, et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122-1128
39. Jansen LA, Uhlmann EJ, Crino PB, Gutmann DH, Wong M (2005) Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1 deficient astrocytes. Epilepsia 46:1871-1880
40. Jones AC, Daniells CE, Snell RG, et al. (1997) Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum Mol Genet 6:2155-2161
41. Jones AC, Shyamsundar MM, Thomas MW, et al. (1999) Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 64:1305-1315
42. Kobayashi T, Minowa O, Sugitani Y, et al. (2001) A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci USA. 98:8762-8767
43. Krueger DA, Care MM, Holland K, et al. (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801-1811
44. Kyin R, Hua Y, Baybis M, Scheithauer B, Kolson D, Uhlmann E, Gutmann D, Crino PB (2001) Differential cellular expression of neurotrophins in cortical tubers of the tuberous sclerosis complex. Am J Pathol 159:1541-1554
45. Lamb RF, Roy C, Diefenbach TJ, et al. (2000) The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2:281-287
46. Larson Y, Liu J, Stevens PD, et al. (2010) Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1. J Biol Chem 285:24987-24998
47. Lee A, Maldonado M, Baybis M, Walsh CA, Scheithauer B, Yeung R, Parent J, Weiner HL, Crino PB (2003) Markers of cellular proliferation are expressed in cortical tubers. Ann Neurol 53(5):668-673
48. Lee-Jones L, Aligianis I, Davies PA, Puga A, Farndon PA, Stemmer-Rachamimov A, Ramesh V, Sampson JR (2004) Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2. Genes Chromosomes Cancer 41:80-85
49. Lopes MB, Altermatt HJ, Scheithauer BW, Shepherd CW, VandenBerg SR (1996) Immunohistochemical characterization of subependymal giant cell astrocytomas. Acta Neuropathol 91:368-375
50. Ma J, Meng Y, Kwiatkowski DJ, et al. (2010) Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Investig 120:103-114
51. Maldonado M, Baybis M, Newman D, Kolson DL, Chen W, McKhann G 2nd, Gutmann DH, Crino PB (2003) Expression of ICAM-1, TNF-alpha, NFkappaB, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol Dis 14:279-290
52. Marcotte L, Aronica E, Baybis M, Crino PB (2012) Cytoarchitectural alterations are widespread in cerebral cortex in tuberous sclerosis complex. Acta Neuropathol 123:685-693
53. McMaster ML, Goldstein AM, Parry DM (2011) Clinical features distinguish childhood chordoma associated with tuberous sclerosis complex (TSC) from chordoma in the general paediatric population. J Med Genet 48:444-449
54. Meikle L, Talos DM, Onda H, et al. (2007) A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 27:5546-5558
55. Miyata H, Chiang AC, Vinters HV (2004) Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis. Ann Neurol 56(4):510-519
56. Mizuguchi M, Takashima S (2001) Neuropathology of tuberous sclerosis. Brain Dev 23(7):508-515
57. Napolioni V, Moavero R, Curatolo P (2009) Recent advances in neurobiology of tuberous sclerosis complex. Brain Dev 31:104-113
58. Nie D, Di Nardo A, Han JM, et al. (2010) Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci 13:163-172
59. Niida Y, Stemmer-Rachamimov AO, Logrip M, Tapon D, Perez R, Kwiatkowski DJ, Sims K, MacCollin M, Louis DN, Ramesh V (2001) Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 69:493-503
60. Oh WJ, Jacinto E (2011) mTOR complex 2 signaling and functions. Cell Cycle 10:2305-2316
61. Onda H, Crino PB, Zhang H, Murphey RD, Rastelli L, Gould Rothberg BE, Kwiatkowski DJ (2002) Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol Cell Neurosci 21(4):561-574
62. Orlova KA, Tsai V, Baybis M, et al. (2010) Early progenitor cell marker expression distinguishes type II from type I focal cortical dysplasias. J Neuropath Exp Neurol 69(8):850-863
63. Osborne JP, Fryer A, Webb D (1991) Epidemiology of tuberous sclerosis. Ann NY Acad Sci 615:125-127
64. Park SH, Pepkowitz SH, Kerfoot C, et al. (1997) Tuberous sclerosis in a 20-week gestation fetus: immunohistochemical study. Acta Neuropathol 94:180-186
65. Parker WE, Orlova KA, Heuer GG, et al. (2011) Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex. Am J Pathol 178:296-305
66. Peterson TR, Laplante M, Thoreen CC, et al. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137:873-886
67. Potter CJ, Huang H, Xu T (2001) Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 105:357-368
68. Prabowo AS, Anink JJ, Lammens M, et al. (2013) Fetal Brain Lesions in Tuberous Sclerosis Complex: TORC1 Activation and Inflammation. Brain Pathol 23:45-49
69. Qin W, Chan JA, Vinters HV, et al. (2010) Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events. Brain Pathol 20:1096-1105
70. Qin W, Kozlowski P, Taillon BE, et al. (2010) Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex. Hum Genet 127:573-582
71. Reith RM, Way S, McKenna J 3rd, Haines K, Gambello MJ (2011) Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration. Neurobiol Dis 43:113-122
72. Ridler K, Bullmore ET, De Vries PJ, et al. (2001) Widespread anatomical abnormalities of grey and white matter structure in tuberous sclerosis. Psychol Med 31:1437-1446
73. Roach ES, Smith M, Huttenlocher P, et al. (1992) Diagnostic criteria: tuberous sclerosis complex. Report of the Diagnostic Criteria Committee of the National Tuberous Sclerosis Association. J Child Neurol 7:221-224
74. Roach ES, Gomez MR, Northrup H (1998) Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 3:624-628
75. Rosner M, Hengstschlager M (2004) Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J Biol Chem 279:48707-48715
76. Rüegg S, Baybis M, Juul H, Dichter M, Crino PB (2007) Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res 77:85-92
77. Sancak O, Nellist M, Goedbloed M, et al. (2005) Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet 13:731-741
78. Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR pathway. Curr Opin Cell Biol 17:596-603
79. Sato N, Koinuma J, Ito T, et al. (2010) Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis. Genes Chromosomes Cancer 49:353-367
80. Sharma M, Ralte A, Arora R, Santosh V, Shankar SK, Sarkar C (2004) Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins. Pathology 36:139-144
81. Sosunov AA, Wu X, Weiner HL, Mikell CB, Goodman RR, Crino PB, McKhann GM 2nd (2008) Tuberous sclerosis: a primary pathology of astrocytes? Epilepsia 49(Suppl 2):53-62
82. Takahashi DK, Dinday MT, Barbaro NM, Baraban SC (2004) Abnormal cortical cells and astrocytomas in the Eker rat model of tuberous sclerosis complex. Epilepsia 45:1525-1530
83. Takei H, Adesina AM, Powell SZ (2009) Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex. Neuropathology 29:181-186
84. Talos DM, Kwiatkowski DJ, Cordero K, Black PM, Jensen FE (2008) Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann Neurol 63:454-465
85. Tavazoie SF, Alvarez VA, Ridenour DA, et al. (2005) Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci 8:1727-1734
86. Tee AR, Manning BD, Roux PP, et al. (2003) Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13:1259-1268
87. Tsai V, Parker WE, Orlova KA, et al. (2012) Fetal Brain mTOR Signaling Activation in Tuberous Sclerosis Complex. Cereb Cortex. October 18 [Epub Ahead of print]
88. Tsai PT, Hull C, Chu Y, et al. (2012) Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 488:647-651. doi: 10.1038/nature11310
89. Tyburczy ME, Kotulska K, Pokarowski P, Mieczkowski J, Kucharska J, Grajkowska W, Roszkowski M, Jozwiak S, Kaminska B (2010) Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. Am J Pathol 176(4):1878-1890
90. Uhlmann EJ, Wong M, Baldwin RL, et al. (2002) Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol 52:285-296
91. van Slegtenhorst M, de Hoogt R, Hermans C, et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805-808
92. van Slegtenhorst M, Verhoef S, Tempelaars A, et al. (1999) Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation. J Med Genet 36:285-289
93. Vaughn J, Hagiwara M, Katz J, Roth J, Devinsky O, Weiner H, Milla S (2012) MRI Characterization and longitudinal study of focal cerebellar lesions in a young tuberous sclerosis cohort. AJNR Am J Neuroradiol. 2012 Sep 6 [Epub ahead of print]
94. Way SW, McKenna J 3rd, Mietzsch U, et al. (2009) Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Genet 18:1252-1265
95. White R, Hua Y, Lynch DR, Scheitauer B, Crino PB (2001) Differential transcription of neurotransmitter receptor subunits and uptake sites in giant cells and dysplastic neurons in cortical tubers. Ann Neurol 49:67-78
96. Wong M, Ess K, Uhlmann EJ, et al. (2003) Impaired astrocyte glutamate transport in a mouse epilepsy model of tuberous sclerosis complex. Ann Neurol 54:251-256
97. Wong M, Crino PB (2012) Tuberous sclerosis and epilepsy: role of astrocytes. Glia 60:1244-1250
98. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471-484
99. Xu L, Zeng LH, Wong M (2009) Impaired astrocyte gap junction coupling and potassium buffering in a mouse model of tuberous sclerosis complex. Neurobiol Dis 34:291-299
100. Yang Q, Inoki K, Kim E, Guan KL (2006) TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc Natl Acad Sci USA 103:6811-6816
101. Yu Y, Yoon SO, Poulogiannis G, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332:1322-1326
102. Yuan E, Tsai PT, Greene-Colozzi E, Sahin M, Kwiatkowski DJ, Malinowska IA (2012) Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features. Hum Mol Genet 21:4286-4300
103. Zeng Z, dos Sarbassov D, Samudio IJ, et al. (2007) Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109:3509-3512
104. Zeng LH, Xu L, Gutmann DH, Wong M (2008) Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 63:444-453
105. Zeng LH, Rensing NR, Zhang B, et al. (2011) Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet 20:445-454
106. Zeng LH, Bero AW, Zhang B, Holtzman DM, Wong M (2010) Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of tuberous sclerosis complex. Neurobiol Dis 37(3):764-771
107. Zhou J, Shrikhande G, Xu J, et al. (2011) Tsc1 mutant neural stem/progenitor cells exhibit migration deficits and give rise to subependymal lesions in the lateral ventricle. Genes Dev 25:1595-1600